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Abstract 
Background: Submicroscopic malaria parasitaemia is common in both high- and low-endemicity settings, but its 
clinical consequences are unclear.
Methods: A cohort of 364 children (0.5–10 years of age) and 106 adults was followed from 2011 to 2016 in Tororo 
District, Uganda using passive surveillance for malaria episodes and active surveillance for parasitaemia. Participants 
presented every 90 days for routine visits (n = 9075); a subset was followed every 30 days. Participants who presented 
with fever and a positive blood smear were treated for malaria. At all routine visits microscopy was performed and 
samples from subjects with a negative blood smear underwent loop-mediated isothermal amplification for detection 
of plasmodial DNA.
Results: Submicroscopic parasitaemia was common; the proportion of visits with submicroscopic parasitemia 
was 25.8% in children and 39.2% in adults. For children 0.5–10 years of age, but not adults, having microscopic and 
submicroscopic parasitaemia at routine visits was significantly associated with both fever (adjusted risk ratios [95% CI], 
2.64 [2.16–3.22], 1.67 [1.37–2.03]) and non-febrile illness (aRR [CI], 1.52 [1.30–1.78], 1.26 [1.09–1.47]), compared to not 
having parasitaemia. After stratifying by age, significant associations were seen between submicroscopic parasitae-
mia and fever in children aged 2–< 5 and 5–10 years (aRR [CI], 1.42 [1.03–1.98], 2.01 [1.49–2.71]), and submicroscopic 
parasitaemia and non-febrile illness in children aged 5–10 years (aRR [CI], 1.44 [1.17–1.78]). These associations were 
maintained after excluding individuals with a malaria episode within the preceding 14 or following 7 days, and after 
adjusting for household wealth.
Conclusions: Submicroscopic malaria infections were associated with fever and non-febrile illness in Ugandan chil-
dren. These findings support malaria control strategies that target low-density infections.
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Background
Despite coordinated efforts in vector-control and 
improved treatment of symptomatic disease, malaria 
infection remains common worldwide, causing an esti-
mated 200 million illnesses per year [1]. The use of 
molecular diagnostic tests such as loop-mediated iso-
thermal amplification (LAMP) and quantitative PCR has 
uncovered a large reservoir of malaria parasites previ-
ously not detectable by microscopy or rapid diagnostic 
test (RDT) [2–4]. There is evidence that these submi-
croscopic infections contribute to disease transmission, 
with insect feeding studies demonstrating human-to-
mosquito transmission in the absence of microscopically 
detectable parasites [5, 6]. However, the clinical relevance 
of submicroscopic infection is less clear. Much of the 
data on submicroscopic infection are from single cross-
sectional surveys, in which the low frequency of clinical 
outcomes may limit the statistical power to study these 
outcomes. Furthermore, molecular detection of low-level 
parasitaemia may represent early detection of replicat-
ing parasites that will ultimately result in clinical disease, 
or detection of gametocytes after successful treatment, 
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and distinguishing these possibilities is not possible 
without longitudinal data. Although there is some evi-
dence to suggest that low-density, chronic infections can 
be accompanied by clinical signs and symptoms, with 
associations suggested between submicroscopic parasi-
taemia and anaemia, altered cognitive function, inflam-
matory markers, and systemic bacterial infection [4, 7, 
8], few studies have included sufficient follow-up to dem-
onstrate the clinical consequences of submicroscopic 
parasitaemia.
To assess associations between submicroscopic para-
sitaemia and clinical outcomes, repeated surveys meas-
uring parasite prevalence were performed in a cohort of 
Ugandan children and adults. We hypothesized that sub-
microscopic malaria infection would be associated with 
clinical outcomes, including fever, in children.
Methods
Ethical approval
The study protocol was reviewed and approved by the 
Uganda National Council of Science and Technology 
(Approval Number HS 1019) and the institutional review 
boards of the University of California—San Francisco 
(Approval Number 11-05995), and Makerere University 
(Approval Number 2011-169). Informed consent was 
obtained from the parent or guardian of all participating 
children.
Study site and participants
The study took place in Nagongera sub-county, Tororo 
District, Uganda, an area where malaria transmission 
has been reported as high and perennial [9], with annual 
entomological inoculation rates of  >  300 bites per per-
son/year in 2011–12 [10]. However, transmission inten-
sity declined dramatically after indoor residual spraying 
of insecticides (IRS) was initiated in December, 2014 
[11]. Samples for this study were from repeated surveys 
in a cohort of children (age 0.5–10  years) and adults 
(age  ≥  18) between August 2011 and June 2016, coin-
ciding with three rounds of IRS in December 2014, June 
2015, and December 2015.
Study design and clinical follow‑up
Cohort enrolment, follow-up, and clinical care have been 
described previously [4, 10]. Briefly, participants were 
recruited from 100 randomly selected households within 
the catchment area of the study health facility. All chil-
dren aged 6 months to 10 years plus a primary adult care-
taker in the household were enrolled. Participants agreed 
to come to the study clinic for any febrile illness and to 
avoid anti-malarial medications administered outside the 
study. All enrolled participants were given a long-lasting 
insecticidal bed net.
Participants presented to the clinic for routine visits 
every 90 days (every 30 days for a subset of 204 patients 
starting in 2015). At each routine visit, clinical interviews 
were performed, and blood smears and dried blood spots 
(DBS) were collected, regardless of symptoms. For sam-
ples with negative blood smears, DNA extracted from 
DBS was tested for the presence of submicroscopic para-
sitaemia using LAMP. Participants were invited to visit 
the clinic any time they were ill, and microscopy was 
performed when there was a reported or documented 
fever (temperature of ≥ 38.0  °C). Patients with reported 
or documented fever and a positive blood smear were 
treated with standard dosing of artemether–lumefan-
trine. Participants with asymptomatic parasitaemia were 
not provided anti-malarial therapy in accordance with 
local standard-of-care.
Laboratory methods
Thick smears were prepared with 2% Giemsa. Two expert 
microscopists evaluated each smear separately, and a 
third resolved discrepancies. DBS were prepared by spot-
ting approximately 25 μL of blood onto filter paper, dry-
ing completely, and storing at room temperature. DNA 
was extracted using Chelex, as previously described [12], 
yielding 200 µL of DNA extraction product. LAMP was 
performed using Eiken Loopamp™ Malaria Pan Detec-
tion Kit reaction tubes and 15 µL of extracted DNA, per 
manufacturer’s guidelines. The LAMP primer set targets 
a mitochondrial DNA sequence that is conserved in four 
major human malaria species [13]. LAMP reactions were 
assessed based on visual detection of fluorescence under 
an ultraviolet lamp. Each batch of 48 LAMP reactions 
included three controls with known Plasmodium falcipa-
rum densities (10 parasites/µL, 1 parasite/µL, and 0 para-
site/µL), as well as one positive and one negative control 
from the Eiken kit.
Data analysis
Data were analysed using STATA (version 13; STATA 
Corp., College Station, TX, USA). The proportion of 
visits with no detectable parasitaemia (negative blood 
smear and negative LAMP reaction), submicroscopic 
parasitaemia (negative blood smear and positive LAMP 
reaction), and microscopic parasitaemia (positive blood 
smear) were made for participants in different age strata. 
Age strata were pre-specified as <2, 2–<  5, 5–10, and 
≥ 18 years, based on local epidemiology explored in prior 
work [4]. The primary outcomes of interest included 
the risk of (1) fever (reported fever in prior 24 h or tem-
perature of  ≥  38.0  °C at routine visit), (2) documented 
fever (temperature of ≥ 38.0 °C at routine visit), and (3) 
non-febrile clinical illness (composite variable based on 
reported abdominal pain, anorexia, vomiting, diarrhoea, 
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cough, headache, joint pain, muscle ache, seizure, or 
jaundice at routine visit) among those with microscopic, 
submicroscopic, and no detectable parasitaemia. Gen-
eralized estimating equation models were used to esti-
mate associations between parasitaemia status and these 
three outcomes to account for repeated measures, using 
binomial outcomes with a log link function, exchange-
able correlation structure, and robust standard error 
estimates. A p value  <  0.05 was considered statistically 
significant. GEE models were first constructed based on 
simple categorization of parasitaemia status at routine 
visits. To differentiate chronic low-density infection from 
either new infection with expanding parasite biomass or 
recently treated infection, participants who developed 
malaria within 14  days before or 7  days after a routine 
visit were excluded, and separate GEE models were re-
constructed for these visits. Because household wealth 
may be independently associated with both exposure to 
malaria parasites and the outcome of fever and/or clini-
cal illness, a wealth index, categorized by tertiles, was 
included as a covariate. Data collection and determina-
tion of the wealth index has been previously described, 
and was based on two surveys: (1) a baseline household 
survey conducted at the time of enrolment, (2) a second 
household survey conducted after 24  months of follow-
up in September–October 2013 [14].
Results
Study enrolment and parasite prevalence
Over 5  years of longitudinal follow-up of 364 children 
and 106 adults, there were a total of 9075 routine visits, 
including 7342 among children 0.5–10  years, and 1733 
among adults ≥ 18 years (Fig. 1). Blood smears and inter-
views were performed at each routine visit, and for vis-
its with negative blood smears, blood was tested for the 
presence of submicroscopic parasitaemia using LAMP. 
Children were parasitaemic at roughly half of all routine 
visits, with 1843 (25.1%) microscopic infections and 1895 
(25.8%) submicroscopic infections (Fig. 2). A similar pro-
portion of adult visits were parasitaemic, but fewer had 
microscopic (106; 6.1%) compared to submicroscopic 
(679; 39.2%) infections. Further stratifying the proportion 
of visits with detectable parasitaemia by age revealed that 
microscopic parasitaemia amongst children increased 
with age, peaking at 28.7% among children 5–10  years 
old, but that submicroscopic infection remained steady, 
with roughly a quarter of children having submicroscopic 
parasitaemia across age groups.
Association of parasitaemia and fever
In children, having microscopic parasitaemia com-
pared to no parasitaemia was, as expected, associated 
with a more than twofold increase in risk of fever in all 
age groups (Table  1). More remarkably, in children age 
2–10  years of age, submicroscopic parasitaemia was 
also associated with an increased risk of fever compared 
to those without parasitaemia (adjusted risk ratio [CI], 
1.42 [1.03–1.98] for age 2–<  5  years, 2.01 [1.49–2.71] 
for age 5–10  years). This association was maintained 
for the same age range when those with recent malaria 
were excluded from the analysis. However, associations 
between submicroscopic parasitaemia and fever were 
not seen among children < 2 years of age or adults. The 
wealth index was not significantly associated with the 
outcome of fever in either univariate or multivariate anal-
ysis, and was not included in the final model.
As malarial fevers are typically intermittent, the usual 
definition for malaria diagnosis includes either history 
of fever or documented fever. However, documented 
fevers were considered as an alternative, more specific 
outcome (see Additional file 1). There were smaller num-
bers for this outcome, which did not allow for age strati-
fication, but the findings were similar to those when all 
fevers were considered. There was again a significant 
association between microscopic parasitaemia and docu-
mented fever in children, compared to no parasitaemia, 
with a > fivefold increase in risk. Among children, having 
submicroscopic parasitaemia compared to no parasitae-
mia was associated with an increased risk of documented 
fever (aRR [CI], 2.08 [1.18–3.66]), and this association 
was maintained when those with recent malaria were 
excluded from the analysis (aRR [CI], 1.87 [1.03–3.37]). 
Neither microscopic nor submicroscopic parasitaemia 
was associated with increased risk of documented fever 
in adults.
Association of parasitaemia and non‑febrile clinical illness
In children of all ages, microscopic parasitaemia was 
associated with an increased risk of non-febrile clini-
cal illness, compared to those without parasitaemia 
(Table  2). However, submicroscopic parasitaemia, com-
pared to no parasitaemia was associated with non-febrile 
clinical illness only in children aged 5–10 years (aRR [CI] 
1.44 [1.17–1.78]). The association in this age group was 
maintained when excluding those with recent malaria. 
Wealth index was not significantly associated with the 
outcome of non-febrile clinical illness in either univariate 
or multivariate analysis, and was not included in the final 
model. For adults, neither microscopic nor submicro-
scopic parasitaemia was associated with increased risk of 
non-febrile clinical illness.
Discussion
It is increasingly appreciated that submicroscopic malaria 
parasitaemia is common in both high- and low-transmis-
sion settings, but the clinical implications of low-level 
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parasitaemia remain unclear [6, 15–17]. This study 
assessed relevant data from repeated surveys in a cohort 
of Ugandan children and adults, followed over 5 years, to 
measure associations between parasitaemia and clinical 
outcomes. The associations between microscopic para-
sitaemia and clinical outcomes in children in this study 
Fig. 1 Study enrolment. The study cohort was comprised of 364 children and 106 adults, who made a total of 9075 routine visits to the study clinic. 
Routine visits were categorized as no parasitaemia (blood smear and LAMP negative), submicroscopic parasitaemia (blood smear negative, LAMP 
positive), or microscopic parasitaemia (blood smear positive). Visits were further categorized based on whether the participant had a symptomatic 
episode of malaria within 14 days before or 7 days following the routine visit
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were expected; malaria is, by definition, microscopic par-
asitaemia plus clinical symptoms. More notably, in chil-
dren submicroscopic parasitaemia was associated with 
an increased risk of both fever and non-febrile illness. 
These results suggest that submicroscopic infections have 
clinically relevant consequences for infected children.
Much of the prior work suggesting clinical conse-
quences of submicroscopic parasitaemia has been based 
on surveys at a single time point, with limited ability to 
characterize these infections. These studies were limited 
by inability to distinguish positive molecular results due 
to low-level active infections, detection of DNA from 
parasites recently eliminated by treatment, or detection 
of gametocyte DNA. The study described here benefitted 
from longitudinal assessment, and therefore the ability to 
control for recent or subsequent malaria infection.
Data from this study joins a body of work suggest-
ing that even low-density microscopic and submicro-
scopic infections can be clinically relevant. Clinical 
consequences of low-density parasitaemia may be due 
to direct effects of parasitaemia or to immune dysregu-
lation related to infection [18] that increases the risk 
of non-malarial infections. It is also possible that the 
observed association does not reflect a causal relation-
ship and that submicroscopic infection is associated 
with other exposures, though there was no apparent 
association with wealth. An early study from the Gam-
bia showed association between malaria parasitaemia, 
including very low-density infections, and non-typhoid 
Salmonella bacteraemia [19]. A more recent study from 
Gabon showed that submicroscopic parasitaemia, identi-
fied by molecular methods, was present in nearly a quar-
ter of all febrile, blood smear negative children surveyed, 
although the study design did not allow for comparison 
of parasite prevalence in non-febrile children [20].
In this study’s cohort, age was a powerful modifying fac-
tor for the association between parasitaemia and clinical 
symptoms. Young children (< 2 years old) had an expected 
association between microscopically detected parasitae-
mia and both fever and non-febrile illness. However, in 
contrast to older children, in these young children submi-
croscopic infection was not associated with either febrile 
or non-febrile illness. Low numbers of children in this age 
group may have prevented the identification of an associa-
tion, but it is possible that the persistence of fetal haemoglo-
bin, or other age-related differences in the immune system 
of infants protected against clinical effects of low-density 
infections [21, 22]. In older children, significant associations 
were seen between submicroscopic parasitaemia and fever 
in children aged 2–< 5 and 5–10 years, and between submi-
croscopic parasitaemia and non-febrile illness in children 
aged 5–10  years. These results are consistent with recent 
findings from Rwanda, where children aged 6–10 with sub-
microscopic infection had more frequent fever, tiredness, 
weakness, poor appetite, and vomiting than among their 
uninfected peers [23]. It is worth noting that submicro-
scopic infection is very common in school-aged children in 
many malaria-endemic areas, [24, 25], so even modest asso-
ciations with clinical consequences may lead to important 
morbidity in this population. In adults, neither microscopic 
nor submicroscopic parasitaemia was associated with an 
increased risk of fever or non-febrile clinical illness, presum-
ably due to effective but non-sterilizing immunity.
The concept that submicroscopic infection has clinical 
consequences strengthens arguments for malaria control 
strategies designed to eliminate all malaria parasitaemia. 
These strategies may include mass drug administration, 
which has been used in Africa intermittently for decades 
[26, 27], or mass and focal screen and treatment strate-
gies, which are being studied in Africa and South East 
Asia [28–30]. Availability of high-sensitivity diagnos-
tics including high-sensitivity RDTs could improve the 
efficacy of these efforts, and awareness that individual 
children may see a health benefit from treating their low-
density infections may enhance acceptance of such strat-
egies by clinicians and local communities. Relevant to 
targeting of these infections, treatment of chronic asymp-
tomatic infection in a setting with seasonal transmission 
did not appear to increase risk of clinical malaria during 
subsequent transmission seasons [31].
Conclusions
This study demonstrates a compelling association 
between submicroscopic malaria infection and clinical ill-
ness in children in a high-burden country. These findings 
highlight the importance of defining the submicroscopic 
Fig. 2 Proportion of study population with microscopic and submicro-
scopic parasitaemia. Participants are divided into age strata along the X 
axis. The percentage of positive samples, among all samples collected at 
routine visits for that age group, is shown on the Y axis
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Table 1 Association between parasitaemia and fever
No parasitaemia Submicroscopic parasitaemia Microscopic parasitaemia
Association between parasitaemia and  fevera
 Age 0.5–< 2
  Risk 37/293 (12.6%) 16/120 (13.3%) 25/71 (35.2%)
  RRb (95% CI) Reference group 1.02 (0.60–1.75) 2.72 (1.71–4.33)
  p value – 0.08 < 0.01
 Age 2–< 5
  Risk 88/1158 (7.6%) 59/508 (11.6%) 81/393 (20.6%)
  RRb (95% CI) Reference group 1.42 (1.03–1.98) 2.56 (1.93–3.37)
  p value – 0.03 < 0.01
 Age 5–10
  Risk 86/2153 (4.0%) 93/1267 (7.34%) 146/1379 (10.6%)
  RRb (95% CI) Reference group 2.01 (1.49–2.71) 2.93 (2.15–3.99)
  p value – < 0.01 < 0.01
 Age 0.5–10
  Risk 211/3604 (5.6%) 168/1895 (8.9%) 252/1843 (13.7%)
  RRb (95% CI) Reference group 1.67 (1.37–2.03) 2.64 (2.16–3.22)
  p value – < 0.01 < 0.01
 Age ≥ 18
  Risk 50/948 (5.2%) 48/679 (7.1%) 8/106 (7.6%)
  RRb (95% CI) Reference group 1.31 (0.23–0.85) 1.47 (0.70–3.06)
  p value – 0.23 0.31
No parasitaemia Submicroscopic parasitaemia
Association between parasitaemia and fever, excluding those with recent  malariac
 Age 0.5–< 2
  Risk 37/284 (13.0%) 14/81 (17.3%)
  RRb (95% CI) Reference group 1.32 (0.76–2.31)
  p value – 0.33
 Age 2–< 5
  Risk 84/1100 (7.6%) 47/378 (12.4%)
  RRb (95% CI) Reference group 1.52 (1.07–2.17)
  p value – 0.02
 Age 5–10
  Risk 79/2034 (3.9%) 89/1161 (7.7%)
  RRb (95% CI) Reference group 1.97 (1.48–2.63)
  p value – < 0.01
 Age 0.5–10
  Risk 200/3418 (5.9%) 150/1620 (9.3%)
  RRb (95% CI) Reference group 1.64 (1.34–2.01)
  p value – < 0.01
 Age ≥ 18
  Risk 48/930 (5.2%) 47/672 (7.0%)
  RRb (95% CI) Reference group 1.31 (0.85–2.05)
  p value – 0.23
a Reported fever in prior 24 h or documented temperature of ≥ 38.0 °C at routine visit
b Adjusted for repeated measures in the same study participant
c Excludes participants who were diagnosed with malaria in the past 14 days or developed malaria in the next 7 days
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malaria parasite reservoir, provide evidence for individ-
ual benefit from treatment of low-density malaria para-
sitaemia, and support aggressive interventions geared to 
eliminate submicroscopic malaria infections.
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